Who
John M. Leonard
President and CEO
Company insider
Files Form 4 as: President and CEO, Intellia Therapeutics; Director, IQVIA Holdings; Director, Chimerix; Director, Vitae Pharmaceuticals; SVP, Chief Scientific Officer, AbbVie.
In numbers
- Trades disclosed
- 206
- Buys
- 2
- Sells
- 33
- Bought
- $163K
- Sold
- $61.5M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 14 Feb 2013
- Last trade
- 21 Aug 2026
- Last filed
- 24 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Aug 2026filed 24 Aug 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $36K2,785 at $13.00 | filing |
| 21 Aug 2026filed 24 Aug 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $36K2,785 at $13.00 | filing |
| 20 Aug 2026filed 24 Aug 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $251K19,890 at $12.60 | filing |
| 20 Aug 2026filed 24 Aug 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $251K19,890 at $12.60 | filing |
| 23 Apr 2026filed 27 Apr 2026 | IQV IQVIA HoldingsLife-science tools | SEC FORM 4 Code A | —1,571 at $0.00 | filing |
| 23 Apr 2026filed 27 Apr 2026 | IQV IQVIA HoldingsLife-science tools | SEC FORM 4 Code A | —1,571 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —156,400 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —225,400 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —225,400 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —156,400 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $314K34,146 at $9.21 | filing |
| 5 Jan 2026filed 7 Jan 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $314K34,146 at $9.21 | filing |
| 12 Dec 2025filed 12 Dec 2025 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —8,557 at $0.00 | filing |
| 12 Dec 2025filed 12 Dec 2025 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code M | $58K8,557 at $6.83 | filing |
| 11 Dec 2025filed 12 Dec 2025 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —49,959 at $0.00 | filing |
| 11 Dec 2025filed 12 Dec 2025 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code M | $341K49,959 at $6.83 | filing |
| 11 Dec 2025filed 12 Dec 2025 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $474K49,959 at $9.49 | filing |
| 11 Dec 2025filed 12 Dec 2025 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $311K32,832 at $9.47 | filing |
| 11 Dec 2025filed 12 Dec 2025 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $51K5,355 at $9.59 | filing |
| 24 Apr 2025filed 25 Apr 2025 | IQV IQVIA HoldingsLife-science tools | SEC FORM 4 Code A | —1,592 at $0.00 | filing |
News
Critical Contrast: Intellia Therapeutics (NASDAQ:NTLA) vs. Neurogene (NASDAQ:NGNE)NTLA · themarketsdaily.com · 24 Oct 2026Contrasting Intellia Therapeutics (NASDAQ:NTLA) and BeyondSpring (NASDAQ:BYSI)NTLA · tickerreport.com · 19 Oct 2026Financial Review: Intellia Therapeutics (NASDAQ:NTLA) versus Spyre Therapeutics (NASDAQ:SYRE)NTLA · themarketsdaily.com · 19 Oct 2026
0 headlines in the last 90 days name John M. Leonard; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.